Results 271 to 280 of about 484,484 (318)

Health economic evaluation of newborn hepatitis B immunization prevention strategies in Ningbo: a Markov modeling study. [PDF]

Front Public Health
Feng W, Li Z, Fan M, Yang S, Shao Y, Liu K, Huang S, Fu S.   +7 more
europepmc   +1 more source

Recommended vaccinations for patients with chronic liver diseases. [PDF]

Clin Exp Hepatol
Janocha-Litwin J, Simon K.
europepmc   +1 more source

Hepatitis B knowledge and stigma in the United Arab Emirates. [PDF]

Sci Rep
Barqawi HJ, Samara KA, Al Ansari MM, Al Moukdad AM, Obied SH, Abu-Gharbieh E.   +5 more
europepmc   +1 more source

Silver Nanoparticle‐Mediated Antiviral Efficacy against Enveloped Viruses: A Comprehensive Review

Global Challenges, EarlyView.
Silver nanoparticles (AgNPs) exhibit broad‐spectrum antiviral activity by targeting key viral structures and processes. They disrupt viral envelopes, compromising integrity, and bind to nucleocapsids, impairing viral replication. AgNPs also inhibit glycoprotein interactions, preventing viral attachment and entry into host cells.
Ekaterine Mosidze, Gianluigi Franci, Federica Dell'Annunziata, Nicoletta Capuano, Marica Colella, Flora Salzano, Massimiliano Galdiero, Aliosha Bakuridze, Veronica Folliero   +8 more
wiley   +1 more source

Chronic hepatitis B virus infection increases the risk of kidney disease while antiviral therapy for hepatitis B virus can decrease kidney disease risk. [PDF]

BMC Nephrol
Ito KL, Zhang Y, Li B, King A, Yee LJ, Frenette C, Abramov F, Flaherty JF, Malkov VA.   +8 more
europepmc   +1 more source

Global burden and trends of viral hepatitis among women of childbearing age from 1990 to 2021. [PDF]

Front Microbiol
Yang S, Zhong L, Huang L, Lin S, Li Y.
europepmc   +1 more source

Association of nucleos(t)ide analogue therapy with Parkinson disease in chronic hepatitis B patients. [PDF]

Sci Rep
Lim J, Lee HY, Sang H, Jeong SJ, Kim HI.
europepmc   +1 more source

A systematic review and meta-analysis assessing the safety and efficacy of the hepatitis E virus vaccine. [PDF]

Proc (Bayl Univ Med Cent)
Mohamed I, Abosheiashaa H, Boda A, Yang F, Kamali E, Scott R, Huntress K, Saravanan T, Saelm AE, Jaber F, Abboud Y, Dahiya D, Alba L, Duong N.   +13 more
europepmc   +1 more source

Quantitative Change of Hepatitis B Surface Antigen Leading to Final Hepatitis B Surface Antigen Loss in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in China. [PDF]

Clin Transl Gastroenterol
Zhou T, Shu M, Luo F, Dong S, Teng J, Du Y, Qiu H, Cai W.   +7 more
europepmc   +1 more source

Validation Study of Scores Predicting Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Nucleos(t)ide Analogues. [PDF]

J Viral Hepat
Inoue J, Minami S, Abe K, Kida M, Haga H, Iino C, Numao H, Kuroda H, Ninomiya M, Tsuruoka M, Sato K, Onuki M, Sawahashi S, Ouchi K, Watanabe K, Akahane T, Kobayashi T, Ohira H, Ueno Y, Masamune A.   +19 more
europepmc   +1 more source